Evidence map›Paper›PMID 35891426›Full record

ArticleViruses2022

Eye Infection with SARS-CoV-2 as a Route to Systemic Immunization?

Norbert Schrage, Joel Blomet, Frank Holzer, A Tromme, F Ectors, Daniel Desmecht

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Norbert SchrageACTO e.V., Karlsburgweg 9, 52070 Aachen, Germany.ORCID 0000-0002-6695-3440
Joel BlometLaboratoires Prevor, Moulin de Verville, 95670 Valmondois, France.
Frank HolzerUrsapharm Arzneimittel GmbH, Industriestraße 35, 66129 Saarbrücken, Germany.
A TrommeCHU Liege, Clinique Veterinaire Universitaire, Quartier Vallee 2 Avenue de Cureghem 3, Sart-Tilman, 4000 Liege, Belgium.
F EctorsCHU Liege, Clinique Veterinaire Universitaire, Quartier Vallee 2 Avenue de Cureghem 3, Sart-Tilman, 4000 Liege, Belgium.
Daniel DesmechtCHU Liege, Clinique Veterinaire Universitaire, Quartier Vallee 2 Avenue de Cureghem 3, Sart-Tilman, 4000 Liege, Belgium.
University of Liège · BEAachener Centrum für Technologietransfer in der Ophthalmologie · DELaboratoire Dielen (France) · FRURSAPHARM (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious diseases of the conjunctiva and cornea usually leave behind both broad local and systemic immunity. Case reports of SARS-CoV-2-positive conjunctivitis with subsequent systemic immunity suggest a new route of immunization preventing the primary infection of the airways. MATERIAL AND

methodsA total of 24 Syrian field hamsters were treated. In systematic animal experiments, we infected the eyes of

resultsThe epi-ocularly infected animals (group 1) showed no clinically visible disease during the ocular infection phase. At most, there was a slightly reduced weight gain compared to the control group (group 3), while the respiratory infected animals (group 2) all lost weight, became lethargic, and slowly recovered after two weeks. After the challenge, none of the animals in groups 1 and 2 became ill again. The animals in the negative control (group 3) all became ill. Cytotoxic antibodies were detectable in the blood of the infected groups before and after challenge, with higher titers in the epi-ocularly infected animals.

conclusionBy epi-ocular infection with SARS-CoV-2, the development of systemic immunity with formation of cytotoxic antibodies without severe general disease could be observed in the experimental animals, which did not induce any more disease upon a second infection in the respiratory tract. Therefore, it can be concluded that a purely epi-ocular infection with SARS-CoV2 only induces a weak disease pattern followed by systemic immunity.

Indexed as

COVID-19Eye InfectionsAnimalsConjunctivaCricetinaeImmunizationMesocricetusRNA, ViralSARS-CoV-2RNA, ViralconjunctivaimmunizationMALTmucosaSARS-CoV-2SARS-CoV-2 conjunctivitis

Identifiers

PMID35891426
PMCPMC9318776
OpenAlexW4283773596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.